CBIO Q4 2021 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$345M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17,625-89.2% YoY

Gross Profit

$17,625100.0% margin

Operating Income

-$17M-98870.2% margin

Net Income

-$17M-98847.1% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

-79.6%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$94M

Total Liabilities

$13M

Stockholders' Equity

$82M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17,625	$162,935	-89.2%
Gross Profit	$17,625	$162,935	-89.2%
Operating Income	-$17M	-$16M	-11.9%
Net Income	-$17M	-$16M	-11.9%